These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20480258)

  • 1. MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.
    Fealey ME; Scheithauer BW; Horvath E; Erickson D; Kovacs K; McLendon R; Lloyd RV
    Endocr Pathol; 2010 Sep; 21(3):161-5. PubMed ID: 20480258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.
    Salehi F; Scheithauer BW; Kovacs K; Horvath E; Syro LV; Sharma S; Manoranjan B; Cusimano M
    Neurosurgery; 2012 Feb; 70(2):491-6; discussion 496. PubMed ID: 21822153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of temozolomide in the treatment of aggressive pituitary tumors.
    Liu JK; Patel J; Eloy JA
    J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.
    Salehi F; Scheithauer BW; Kros JM; Lau Q; Fealey M; Erickson D; Kovacs K; Horvath E; Lloyd RV
    J Neurooncol; 2011 Sep; 104(3):647-57. PubMed ID: 21311951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.
    Kovacs K; Scheithauer BW; Lombardero M; McLendon RE; Syro LV; Uribe H; Ortiz LD; Penagos LC
    Acta Neuropathol; 2008 Feb; 115(2):261-2. PubMed ID: 17926052
    [No Abstract]   [Full Text] [Related]  

  • 6. The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy.
    Wang Y; Li J; Tohti M; Hu Y; Wang S; Li W; Lu Z; Ma C
    J Exp Clin Cancer Res; 2014 Jul; 33(1):56. PubMed ID: 25027022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.
    Zuhur SS; Tanik C; Karaman Ö; Velet S; Çil E; Öztürk FY; Özkayalar H; Müslüman AM; Altuntaş Y
    Endocrine; 2011 Oct; 40(2):222-7. PubMed ID: 21792693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.
    Lau Q; Scheithauer B; Kovacs K; Horvath E; Syro LV; Lloyd R
    Pituitary; 2010 Dec; 13(4):367-79. PubMed ID: 20740317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome.
    Salehi F; Scheithauer BW; Moyes VJ; Drake WM; Syro LV; Manoranjan B; Sharma S; Horvath E; Kovacs K
    Endocr Pathol; 2010 Dec; 21(4):227-9. PubMed ID: 21061089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
    Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
    Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of pituitary neoplasms with temozolomide: a review.
    Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
    Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression.
    Chen W; Xiao Z; Zhao Y; Huang L; Du G
    Oncol Rep; 2013 Nov; 30(5):2495-501. PubMed ID: 23970362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MGMT immunoexpression in adamantinomatous craniopharyngiomas.
    Zuhur SS; Müslüman AM; Tanık C; Karaman O; Oztürk FY; Ozderya A; Ozkayalar H; Aydın Y; Altuntaş Y
    Pituitary; 2011 Dec; 14(4):323-7. PubMed ID: 21318329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
    Sardi I; Cetica V; Massimino M; Buccoliero AM; Giunti L; Genitori L; Aricò M
    Oncol Rep; 2009 Oct; 22(4):773-9. PubMed ID: 19724855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
    Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
    Spiegl-Kreinecker S; Pirker C; Filipits M; Lötsch D; Buchroithner J; Pichler J; Silye R; Weis S; Micksche M; Fischer J; Berger W
    Neuro Oncol; 2010 Jan; 12(1):28-36. PubMed ID: 20150365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of MGMT methylation status in pituitary adenoma.
    Arya S; Majaid MA; Shwetha SD; Sravani K; Arivazhagan A; Sampath S; Santosh V
    Pathol Res Pract; 2014 Jul; 210(7):407-11. PubMed ID: 24690322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
    Micko ASG; Wöhrer A; Höftberger R; Vila G; Marosi C; Knosp E; Wolfsberger S
    Pituitary; 2017 Dec; 20(6):643-653. PubMed ID: 28900805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
    Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
    Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
    Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.